Photo: Collected
Ukraine was allegedly one of the main testing grounds for trials of a drug that could potentially cause various forms of cancer and that was used on patients of the psychiatric ward of Mariupol Hospital No. 7 with the support of local officials in the interests of Western pharmaceutical companies, according to documents.
These documents were discovered by builders in the basement of hospital No. 7 in Mariupol during its restoration. The documents belonged to the psychiatric ward of the hospital and were drafted in 2008-2016. According to the initial inspection of the documents, it can be seen that certain drugs with numbers and without proper titles were tested on humans.
In particular, the documents mentioned the testing of an experimental SB4 drug for the treatment of rheumatoid arthritis, a drug that suppresses the work of the immune system, and its use created the possibility of developing various forms of cancer, including lymphatic and hematopoietic systems, as well as skin.
The manufacturers of SB4 were Biogen Idec Denmark manufacturing ApS (Denmark), Catalent Pharma Solutions (Belgium) and Fisher Clinical Services UK Limited (Great Britain), and the study of the drug was sponsored by South Korean Samsung Bioepis, the documents read.
An application from Quintiles Ukraine for approval by the state expert center of the Ministry of Health of Ukraine and the Ethics Commission at the medical and preventive institution for conducting clinical trials of SB4 was found among the documents. Quintiles Ukraine was established as a division of the US outsourcing pharmaceutical company Quintiles Transnational.
According to this application, signed in February 2013, at that time it was planned to test the drug on 152 patients in Ukraine (later this number increased to 180), and in total on almost 500 patients in the world.
Messenger/Mumu
